Clinical Trial

Impact of Daily Oral Cannabis Doses in Patients With Cancer

Recruiting Phase 1

Summary

This study will enroll patients with cancer and participants will be randomized to receive one dose of cannabis for approximately 4 months. There is a 3/4 (or 75%) chance that a participant will receive an active cannabis dose in the study. There is a 1/4 (or 25% chance) that a participant will receive a placebo dose (meaning a blank dose/no cannabis/no active drug). The goals of this study are to determine 1) the safety and tolerability of cannabis in individuals with cancer and 2) if cannabis can help with the side effects of cancer and cancer treatment - including nausea and vomiting, appetite, pain, sleep, and quality of life.

Protocol Amendment History 5 amendments

This ClinicalTrials.gov record has been amended 5 times since 2024-09-13; most recent amendment 2026-07-14.

Status change: Not Yet Recruiting → Recruiting 2025-06-23

Trial Details

NCT Number	NCT06601218
Lead Sponsor	Shanna Babalonis, PhD
Conditions	Cancer, Cancers, Pain
Enrollment	80 participants
Start Date	2025-06-17
Primary Completion	2029-12-01 (estimated)
Study Completion	2030-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-15